Business
Arecor to present on Investor Meet Company
Arecor to present on Investor Meet Company.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nArecor to present on Investor Meet Company platform\n \nCambridge, UK, 24 April 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will be providing a live presentation of the Group's recently announced final results for the year ended 31 December 2024 via the Investor Meet Company platform on Thursday 1 May 2025 at 2pm BST.\n \nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 30 April 2025, 09:00 BST, or at any time during the live presentation.\n \nTo sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit:\nhttps://www.investormeetcompany.com/companies/arecor-therapeutics-plc\n \nInvestors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.\n \n-ENDS-\n \nFor more information, please contact:\n \n\n\n\n\nArecor Therapeutics plc\n\n\nwww.arecor.com\n\n\n\n\nDr Sarah Howell, Chief Executive Officer\n\n\nTel: +44 (0) 1223 426060\nEmail: [email protected]\n\n\n\n\nDavid Ellam, Chief Financial Officer\n\n\nTel: +44 (0) 1223 426060\nEmail: [email protected] \n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets Advisory LLP (NOMAD and Broker)\n\n\n\n\n\n\n\nPhil Davies, Sam Butcher\n\n\nTel: +44 (0) 20 7496 3000\n\n\n\n\n \n\n\n\n\n\n\n\nICR Healthcare\n\n\n\n\n\n\n\nChris Gardner, David Daley, Lindsey Neville\n\n\nTel: +44 (0) 20 3709 5700\nEmail: [email protected] \n\n\n\n\n \n\n\n\n\n\n\n\nNotes to Editors\n \nAbout Arecor\nArecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported b...